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Silica nanoparticles (SNPs) of controllable size, shape and porosity had shown to be a useful 
platform for different uses. In recent years our group studied and developed SNP-based systems, 
functionalizing, loading and embedding SNPs for different purposes.1  
As far as biomedical applications are concerned, the surface modification of SNPs with molecules 
for active targeting has turned out to be a desirable step. For this purpose we selected Boletus 
Edulis Lectin (BEL), since it shows T-antigen recognition capabilities together with antiproliferation 
activity.2 Systems composed of silica functionalized with lectin molecules have been already 
described in literature, for chromatography applications or assay probes. Nonetheless, to the best 
of our knowledge, no one has ever performed the grafting of lectins onto SNPs obtaining a 
functional system to be used in nanomedicine.  
The aim of our research is the creation of a theranostic system, composed of SNPs suitably 
tailored with BEL, and carrying contrast agents and/or therapeutic 
phases. The tethering of PEG molecules on the nanoparticles 
surface will be performed in order to impart stealth properties, steric 
stabilization to the system and reduce citotoxicity. 
Herein we present the first results of this research. The grafting of 
BEL has been attempted via two bioconjugation routes: the first relies 
on in situ reduction of the Schiff base generated from the reaction 
between protein's amine groups and aldehydic functionalities on 
previously modified silica surface. The second protocol is the well-
established reaction involving EDC coupling, eventually in presence 
of NHS3. Coomassie Brilliant blue assay was performed to have a 
qualitative indication of the success of bioconjugation protocols. A 
surface coverage of 8,72 nmol of lectins per mg of SNPs was 
estimated from spectrofluorimetric assays recording the emission of 
protein's tryptophans on modified SNPs, having a diameter of 
around 150 nm. The permanence of the diameter of the particles 
after their superficial modification was confirmed by DLS 
measurements, while ζ-potential analyses showed a slightly 
negative potential in both values measured before and after 
modification. 
At the same time, PEGylation was successfully performed on pristine SNPs with a co-
condensation process, which allowed to obtain fairly monodisperse SNPs covered with a polymer 
layer, as confirmed by TEM observations, IR spectroscopy and cell viability tests. 
Although some issues have been encountered, like the presence of some aggregates during the 
grafting of lectins and a partial loss of the activity of BEL, we foresee the possibility of combining 
the two procedures creating an efficient and multi-purpose theranostic nano-carrier. 
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Figure 1. TEM micrograph 
of SNPs (upper part) and 
photograph of Coomassie 
colored wells  of nanoparticle 
before (A) and after (B) 
lectins surface grafting. 
